Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

被引：12
|
作者：
Lim, Emerson A.
Schweizer, Michael Thomas
Chi, Kim N.
Aggarwal, Rahul Raj
Agarwal, Neeraj
Gulley, James L.
Attiyeh, Edward F.
Greger, James
Wu, Shujian
Jaiprasart, Pharavee
Loffredo, John
Bandyopadhyay, Nibedita
Xie, Hong
Hansen, Aaron Richard
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Univ British Columbia, BC Canc Agcy, Vancouver, BC, Canada
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[6] NCI, NIH, Bethesda, MD 20892 USA
[7] Janssen Res & Dev, Spring House, PA USA
[8] Janssen Res & Dev, Horsham, PA USA
[9] Janssen Res & Dev, Raritan, NJ USA
[10] Janssen Res & Dev LLC, Spring House, PA USA
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
279
引用
收藏
页数：3
相关论文
共 28 条
  • [11] Real Life treatment sequences and survival of men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabazitaxel in UK clinical practice
    Pan, S.
    Bahl, A.
    Gee, A.
    Butt, M.
    Malik, Z.
    Dew, R.
    Birtle, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S493 - S494
  • [12] Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
    Geva, Ravit
    Vieito, Maria
    Ramon, Jorge
    Perets, Ruth
    Pedregal, Manuel
    Corral, Elena
    Doger, Bernard
    Calvo, Emiliano
    Bardina, Jorge
    Garralda, Elena
    Brown, Regina J.
    Greger, James G.
    Wu, Shujian
    Steinbach, Douglas
    Yao, Tsun-Wen Sheena
    Cao, Yu
    Lauring, Josh
    Chaudhary, Ruchi
    Patel, Jaymala
    Patel, Bharvin
    Moreno, Victor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [13] ANALYSIS OF THE USA POSTMARKETING SAFETY PROFILE OF CABAZITAXEL IN THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINING TREATMENT REGIMEN
    Nicacio, L.
    Raina, P.
    Sands, R.
    Neibart, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 312 - 313
  • [14] Real life treatment sequences and survival of men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabazitaxel in clinical practice across England.
    Birtle, Alison J.
    Bahl, Amit
    Butt, Mohammad
    Pan, Shermaine
    Carter, Angela M.
    Thomson, Alastair H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [15] Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC).
    Drake, Charles G.
    Pachynski, Russell Kent
    Subudhi, Sumit Kumar
    McNeel, Douglas G.
    Antonarakis, Emmanuel S.
    Bauer, Todd Michael
    Patricia, Daniel
    Wade, Mark
    Zudaire, Enrique
    Mason, Gary
    Knoblauch, Roland Elmar
    Stone, Nicole L.
    Infante, Jeffrey R.
    Gottardis, Marco
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [16] A single centre review of the NICE approved, standard of care, treatment cost savings for patients with metastatic castrate-resistant prostate cancer (mCRPC) enrolled in clinical trials
    McDonald, Louisa
    Gomm, Nicholas
    Soma, Anita
    BRITISH JOURNAL OF CANCER, 2019, 121 : 29 - 29
  • [17] High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
    Hofman, Michael
    Violet, John
    Sandhu, Shahneen
    Ferdinandus, Justin
    Thang, Sue Ping
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Tim
    Jackson, Price
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [18] Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
    Vaishampayan, Ulka
    Thakur, Archana
    Rathore, Ritesh
    Kouttab, Nicola
    Lum, Lawrence G.
    PROSTATE CANCER, 2015, 2015
  • [19] The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
    Masha Maharaj
    Lucille Heslop
    Trisha Govender
    Nisaar Korowlay
    Aviral Singh
    Partha Choudhary
    Mike Sathekge
    Nuclear Medicine and Molecular Imaging, 2021, 55 : 136 - 140
  • [20] Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC.
    Pak, S.
    Reed, M.
    Luther, M.
    Averia, M.
    Desai, S.
    Pinski, J. K.
    Dorff, T. B.
    Quinn, D. I.
    Chan, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
123